OrbusNeich said it has wrapped up enrollment in a 1,000 patient post-marketing registry to evaluate its innovative Combo dual-therapy stent in real-world conditions over the next few years.
Falling sales of personal computers have chipped away at one of the cornerstones of Intel's business over the past few years. The chipmaker has responded by diversifying and this week made three such moves, each of which has implications for the life sciences sector.
International researchers led by Michigan's Beaumont Health System discovered two biomarkers that helped predict resistance to radiation therapy for patient's with squamous cell cancer of the head and neck.
Global CRO Covance is expanding its heft in biologics development, plotting to double its capacity over the next 5 years.
U.K. researchers have made advances developing a blood test that could screen for patients who have a genetic predisposition to obesity. Their work, published in the journal Diabetes, involves a team from the University of Southampton, University of Exeter Medical School and elsewhere.
Medtronic said it has begun enrollment of what will be a 4,800-patient clinical trial designed to better identify patients at major risk in developing countries for sudden cardiac arrest.
Denmark's Genmab is rolling right along with breakthrough-designated daratumumab for double refractory multiple myeloma, hitting a milestone in Phase II development and triggering a $22 million payout from collaborator Johnson & Johnson.
Pfizer says the Phase IIb study for its closely-watched PCSK9 cholesterol drug bococizumab (RN316) scored the primary endpoint on all doses, which should help steer a massive Phase III program that started out last fall with 22,000 patients.
Translating all the information from the genomics revolution into verifiable drug targets has proven to be no easy task. Now, in an effort to bend the curve toward R&D success, GlaxoSmithKline is teaming up with external experts, putting up money and brainpower to launch a collaborative research effort.
After collaborating with the University of Michigan-spinout NanoBio over the past three years, Merck has signed off on a new licensing pact for the biotech's nanoemulsion adjuvant technology.